IL-10 mediates sigma1 receptor-dependent suppression of antitumor immunity

Journal of Immunology

Volumn 170, Issue 7, 2003, Pages 3585-3591

  Zhu, Li X ^a   Sharma, Sherven ^a,b   Gardner, Brian ^a,b   Escuadro, Brian ^a   Atianzar, Kimberly ^a   Tashkin, Donald P ^a   Dubinett, Steven M ^a,b  

^a UNIVERSITY OF CALIFORNIA   (United States)

^b VA GREATER LOS ANGELES HEALTHCARE SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 PHENYLCYCLOHEXANECARBOXYLIC ACID 2 MORPHOLINOETHYL ESTER; 4 IBP; COCAINE; COMPLEMENTARY DNA; GAMMA INTERFERON; INTERLEUKIN 10; MESSENGER RNA; N ALLYLNORMETAZOCINE; N [2 (2,3 DICHLOROPHENYL)ETHYL] 2 DIMETHYLAMINO N METHYLETHYLAMINE; OPIATE AGONIST; OPIATE ANTAGONIST; PERTUSSIS TOXIN; PROSTAGLANDIN E2; SIGMA 1 OPIATE RECEPTOR; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; CARCINOGENICITY; CONTROLLED STUDY; CYTOKINE PRODUCTION; ENZYME IMMUNOASSAY; ENZYME LINKED IMMUNOSORBENT ASSAY; IMMUNE RESPONSE; IN VITRO STUDY; IN VIVO STUDY; LUNG CANCER; LYMPHOCYTE; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SPLEEN CELL; TUMOR GROWTH; TUMOR IMMUNITY;

EID: 0347296194     PISSN: 00221767     EISSN: None     Source Type: Journal    
DOI: 10.4049/jimmunol.170.7.3585     Document Type: Article

References (60)

1. Bowen, W. D. 2000. Sigma receptors: recent advances and new clinical potentials. Pharm. Acta Helv. 74:211.
2. Walker, J. M. W. D. Bowen, F. O. Walker, R. R. Matsumoto, B. De Costa, and K. C. Rice. 1990. Sigma receptors: biology and function. Pharmacol. Rev. 42:355.
3. Itzhak, Y., ed. 1994. The Sigma Receptors: Neuroscience Perspective Series. 1st Ed. Academic Press Inc., Orlando.
4. Bourrie, B., M. Bouaboula, J, M. Benoit, J. M. Derocq, M. Esclangon, G. Le Fur, and P. Casellas. 1995. Enhancement of endotoxin-induced interleukin-10 production by SR 31747A, a sigma ligand. Eur. J. Immunol. 25:2882.
5. Carayon, P., M. Bouaboula, J. F. Loubet, B. Bourrie, G. Petitpretre, G. Le Fur, and P. Casellas. 1995. The sigma ligand SR 31747 prevents the development of acute graft-versus-host disease in mice by blocking IFN-γ and GM-CSF mRNA expression. Int. J. Immunopharmacol. 17:753.
6. Xu, W., T. Flick, J. Mitchel, C. Knowles, and K. Ault. 1999. Cocaine effects on immunocompetent cells: an observation of in vitro cocaine exposure. Int. J. Immunopharmacol. 21:463.
7. Pellegrino, T., and B. M. Bayer. 1998. In vivo effects of cocaine on immune cell function. J. Neuroimmunol. 83:139.
8. Miller, P. W., S. Sharma, M. Stolina, L. H. Butterfield, J. Luo, Y. Lin, M. Dohadwala, R. K. Batra, L. Wu, J. S. Economou, and S. M. Dubinett. 2000. Intratumoral administration of adenoviral interleukin 7 gene-modified dendritic cells augments specific antitumor immunity and achieves tumor eradication. Hum. Gene Ther. 11:53.
9. Sharma, S., P. Miller, M. Stolina, L. Zhu, M. Huang, R. Paul, and S. Dubinett, 1997. Multi-component gene therapy vaccines for lung cancer: effective eradication of established murine tumors in vivo with interleukin 7/herpes simplex thymidine kinase-transduced autologous tumor and ex vivo-activated dendritic cells. Gene Ther. 4:1361.
10. Stolina, M., S. Sharma, Y. Lin, M. Dohadwala, B. Gardner, J. Luo, L. Zhu, M. Kronenberg, P. W. Miller, J. Portanova, J. C. Lee, and S. M. Dubinett. 2000. Specific inhibition of cyclooxygenase 2 restores antitumor reactivity by altering the balance of IL-10 and IL-12 synthesis. J. Immunol. 164:361.
11. Gardner, B., L. X. Zu, S. Sharma, Q. Liu, A. Makriyannis, D. P. Tashkin, and S. M. Dubinett. 2002. Autocrine and paracrine regulation of lymphocyte CB2 receptor expression by TGF-β, Biochem. Biophys. Acta 290:91.
12. Liu, Y., B. B. Whitlock, J. A. Pultz, and S. A. Wolfe, Jr. 1995. Sigma-1 receptors modulate functional activity of rat splenocytes. J. Neuroimmunol. 59:143.
13. Wang, Y., D. S. Huang, and R. R. Watson. 1994. In vivo and in vitro cocaine modulation on production of cytokines in C57BL/6 mice. Life Sci. 54:401.
14. Proft, T., and J. Fraser. 1998. Superantigens: just like peptides only different. J. Exp. Med. 187:819.
15. Miller, C., J. A. Ragheb, and R. H. Schwartz. 1999. Anergy and cytokine-mediated suppression as distinct superantigen-induced tolerance mechanisms in vivo. J. Exp. Med. 190:53.
16. Bourrie, B., J. M. Benoit, J. M. Derocq, M. Esclangon, C. Thomas, G. Le Fur, and P. Casellas. 1996. A sigma ligand. SR 31747A, potently modulates Staphylococcal enterotoxin B-induced cytokine production in mice. Immunology 88:389.
17. Rohrer, J. W., and J. H. Coggin, Jr. 1995. CD8 T cell clones inhibit antitumor T cell function by secreting IL-10. J. Immunol. 155:5719.
18. Sharma, S., M. Stolina, Y. Lin, B. Gardner, P. W. Miller, M. Kronenberg, and S. M. Dubinett. 1999. T cell-derived IL-10 promotes lung cancer growth by suppressing both T cell and APC function. J. Immunol. 163:5020.
19. Ganapathy, M. E., P. D. Prasad, W. Huang, P. Seth, F. H. Leibach, and V. Ganapathy. 1999. Molecular and ligand-binding characterization of the sigma-receptor in the Jurkat human T lymphocyte cell line. J. Pharmacol. Exp. Ther. 289:251.
20. +-pentazocine and sigma ligands. Immunology 77:527.
21. Casellas, P., B. Bourrie, X. Canat, P. Carayon, I. Buisson, R. Paul, J. Breliere, and G. Le Fur. 1994. Immunopharmacological profile of SR 31747: in vitro and in vivo studies on humoral and cellular responses. J. Neuroimmunol. 52:193.
22. +-azidophenazocine-sensitive sigma receptor on splenic lymphocytes. J. Immunol. 151:4672.
23. Su, T. P., E. D. London, and J. H. Jaffe. 1988. Steroid binding at sigma receptors suggests a link between endocrine, nervous, and immune systems. Science 240:219.
24. Sharkey, J., K. A. Glen, S. Wolfe, and M. J. Kuhar. 1988. Cocaine binding at sigma receptors. Eur. J. Pharmacol. 149:171.
25. Matsumoto, R. R., K. A. McCracken, M. J. Friedman, B. Pouw, B. R. De Costa, and W. D. Bowen. 2001. Conformationally restricted analogs of BD1008 and an antisense oligodeoxynucleotide targeting sigmal receptors produce anti-cocaine effects in mice. Eur. J. Pharmacol. 419:163.
26. Ujike, H., S. Kuroda, and S. Otsuki. 1996. Sigma receptor antagonists block the development of sensitization to cocaine. Eur. J. Pharmacol. 296:123.
27. Romieu, P., R. Martin-Fardon, and T. Maurice. 2000. Involvement of the sigma1 receptor in the cocaine-induced conditioned place preference. NeuroReport 11:2885.
28. McCracken, K. A., W. D. Bowen, and R. R. Matsumoto. 1999. Novel sigma receptor ligands attenuate the locomotor stimulatory effects of cocaine. Eur. J. Pharmacol. 365:35.
29. Watzl, B., and R. R. Watson. 1990. Immunomodulation by cocaine: a neuroendocrine mediated response. Life Sci. 46:1319.
30. Colombo, L., M. Lopez, G. Chen, and R. Watson. 1999. Effect of short-term cocaine administration on the immune system of young and old C57BL/6 female mice. Immunopharmacol. Immunotoxicol. 21:755.
31. Baldwin, G. C., D. M. Buckley, M. D. Roth, E. C. Kleerup, and D. P. Tashkin. 1997. Acute activation of circulating polymorphonuclear neutrophils following in vivo administration of cocaine: a potential etiology for pulmonary injury. Chest 111:698.
32. Mao, J. T., M. Huang, J. Wang, S. Sharma, D. P. Tashkin, and S. M. Dubinett. 1996. Cocaine down-regulates IL-2-induced peripheral blood lymphocyte IL-8 and IFN-γ production. Cell. Immunol. 172:217.
33. Mao, J., L. Zhu, S. Sharma, K. Chen, M. Huang, S. Santiago, J. Gulsurd, D. Tashkin, and S. Dubinett. 1997. Cocaine inhibits human endothelial cell IL-8 production: the role of transforming growth factor-β. Cell. Immunol. 181:38.
34. 2+ concentration. J. Pharmacol. Exp. Ther. 293:788.
35. 1 receptor at endoplasmic reticulum and nuclear envelope level. Eur. J. Biochem. 263:377.
36. 1 receptors. Trends Pharmacol. Sci. 22:456.
37. Vilner, B. J., C. S. John, and W. D. Bowen. 1995. Sigma-1 and sigma-2 receptors are expressed in a wide variety of human and rodent tumor cell lines. Cancer Res. 55:408.
38. Crawford, K. W., and W. D. Bowen. 2002. Sigma-2 receptor agonists activate a novel apoptotic pathway and potentiate antineoplastic drugs in breast tumor cell lines. Cancer Res. 62:313.
39. 2 enhance peripheral blood lymphocyte IL-10 transcription and protein production. J. Immunol. 157:5512.
40. de Waal-Malefyt, R., J. Haanen, H. Spits, M. G. Roncarolo, A. Te Velde, C. Fidgor, K. Johnson, R. Kastelein, H. Yssel, and J. E. De Vries. 1991. Interleukin-10 (IL-10) and viral IL-10 strongly reduce antigen-specific human T-cell proliferation by diminishing the antigen-presenting capacity of monocytes via down-regulation of class-II major histocompatibility complex expression. J. Exp. Med. 174:915.
41. Taga, K., and G. Tosato. 1992. IL-10 inhibits human T cell proliferation and IL-2 production. J. Immunol. 148:1143.
42. Fiorentino, D. F., A. Zlotnik, T. R. Mosmann, M. Howard, and A. Ogarra. 1991. IL-10 inhibits cytokine production by activated macrophages. J. Immunol. 147:3815.
43. Mosmann, T., and K. W. Moore. 1991. The role of IL-10 in cross-regulation of TH1 and TH2 responses. Immunol. Today 12:A49.
44. Matsuda, M., F. Salazar, M. Petersson, G. Masucci, J. Hansson, P. Pisa, Q. Zhang, M. G. Masucci, and R. Kiessling. 1994. Interleukin 10 pretreatment protects target cells from tumor- and allo-specific cytotoxic T cells and down-regulates HLA class I expression. J. Exp. Med. 180:2371.
45. Salazar-Onfray, F., M. Petersson, L. Franksson, M. Matsuda, T. Blankenstein, K. Kärre, and R. Kiessling. 1995. IL-10 converts mouse lymphoma cells to a CTL-resistant, NK-sensitive phenotype with low but peptide-inducible MHC class I expression. J. Immunol. 154:6291.
46. Kim, J., R. L. Modlin, R. L. Moy, S. M. Dubinett, T. McHugh, B. J. Nickoloff, and K. Uyemura. 1995. IL-10 production in cutaneous basal and squamous cell carcinomas: a mechanism for evading the local T cell immune response. J. Immunol. 155:2240.
47. Hagenbaugh, A., S. Sharma, S. Dubinett, S. H.-Y. Wei, R. Aranda, H. Cheroutre, D. Fowell, S. Binder, B. Tsao, R. Locksley, K. Moore, and M. Kronenberg. 1997. Altered immune responses in IL-10 transgenic mice. J. Exp. Med. 185:2101.
48. Halak, B. K., H. C. Maguire, Jr., and E. C. Lattime. 1999. Tumor-induced interleukin-10 inhibits type I immune responses directed at a tumor antigen as well as a non-tumor antigen present at the tumor site. Cancer Res. 59:911.
49. 2. J. Immunol. 153:1674.
50. Maeda, H., and A. Shiraishi. 1996. TGF-β contributes to the shift toward Th2-type responses through direct and IL-10 mediated pathways in tumor-bearing mice. J. Immunol. 156:73.
51. Huang, M., M. Stolina, S. Sharma, J. Mao, L. Zhu, P. Miller, J. Wollman, H. Herschman, and S. Dubinett. 1998. Non-small cell lung cancer cyclooxygenase-2-dependent regulation of cytokine balance in lymphocytes and macrophages: up-regulation of interleukin 10 and down-regulation of interleukin 12 production. Cancer Res. 58:1208.
52. Seo, N., Y. Tokura, M. Takigawa, and K. Egawa. 1999. Depletion of IL-10- and TGF-β-producing regulatory γδ T cells by administering a daunomycin-conjugated specific monoclonal antibody in early tumor lesions augments the activity of CTLs and NK cells. J. Immunol. 163:242.
53. de Visser, K. E., and W. M. Kast. 1999. Effects of TGF-β on the immune system: implications for cancer immunotherapy. Leukemia 13:1188.
54. Pardoux, C., C. Asselin-Paturel, J. Chehimi, F. Gay, F. Mami-Chouaib, and S. Chouaib. 1997. Functional interaction between TGF-β and IL-12 in human primary allogeneic cytotoxicity and proliferative response. J. Immunol. 158:136.
55. Fargeas, C., C. Y. Wu, T. Nakajima, D. Cox, T. Nutman, and G. Delespesse. 1992. Differential effect of transforming growth factor β on the synthesis of Th1-and Th2-like lymphokines by human T lymphocytes. Eur. J. Immunol. 22:2173.
56. Bogdan, C., and C. Nathan. 1993. Modulation of macrophage function by transforming growth factor β, interleukin-4, and interleukin-10. Ann. NY Acad. Sci. 685:713.
57. 2 production by non-small cell lung cancer cells regulates matrix metalloproteinase-2 and CD44 in cyclooxygenase-2-dependent invasion. J. Biol. Chem. 277:50828.
58. Fligiel, S. E., M. D. Roth, E. C. Kleerup, S. H. Barsky, M. S. Simmons, and D. P. Tashkin. 1997. Tracheobronchial histopathology in habitual smokers of cocaine, marijuana, and/or tobacco. Chest 112:319.
59. Barsky, S., M. Roth, E. Kleerup, M. Simmons, and D. Tashikin. 1998. Histopathologic and molecular alterations in bronchial epithelium in habitual smokers of marijuana, cocaine, and/or tobacco. J. Natl. Cancer Inst. 90:1198.
60. Mao, L., and Y. Oh. 1998. Does marijuana or crack cocaine cause cancer? J. Natl. Cancer Inst. 90:1182.